PTI Proteostasis Therapeutics Inc.

3.55
-0.24  -6%
Previous Close 3.79
Open 3.74
Price To Book 2.59
Market Cap 181,507,865
Shares 51,128,976
Volume 10,821,050
Short Ratio
Av. Daily Volume 2,209,451
Stock charts supplied by TradingView

NewsSee all news

  1. Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BOSTON, Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

    BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

    BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  5. Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

    BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.
PTI-428
Cystic fibrosis
Development to be discontinued due to lack of efficacy - March 25, 2019.
PTI-801 + Symdeko
Cystic fibrosis
Proceed to 28 day studies to confirm efficacy.
PTI-801 and PTI-808
Cystic fibrosis
Phase 2 data due 4Q 2019.
PTI-428 + PTI-801 + PTI-808
Cystic fibrosis
Development to be discontinued due to lack of efficacy.
PTI-428 + Symdeko
Cystic fibrosis

Latest News

  1. Proteostasis Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BOSTON, Dec. 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  2. Proteostasis Therapeutics Regains Compliance with Nasdaq Listing Standards

    BOSTON, Dec. 2, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  3. Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  4. Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

    BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  5. Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

    BOSTON, Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  6. Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    BOSTON, Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic

  7. Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

    BOSTON, Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic